Q3 2025 Management View John Hanna, President and CEO, reported "a strong third quarter on many fronts, including record ...

Castle Biosciences Q3 2025 results: strong test volume growth, raised revenue guidance, and AdvanceAD-Tx launch.

Discover GeneDx’s Q3 2025 earnings highlights: record revenue growth, increased guidance, FDA validations, and expansion in precision medicine.

FRIENDSWOOD, Texas, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its ...

Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the third quarter ended September 30, 2025.

Aehr Test Systems reports Q2 EPS of 23 cents, versus 19 cents, and revenue of $21.40 million, versus $20.89 million. The company states it anticipates an impact to its full-year revenue due to a delay ...

CAMBRIDGE, England--(BUSINESS WIRE)--Today AstraZeneca revealed its bold ambition to deliver $80 billion in Total Revenue by 2030, up from $45.8 billion in 2023. This will be achieved through ...

Q3 2025 Management View CEO Luis Müller highlighted "recurring revenue continued to grow for the third consecutive quarter, driven by strength in interface solutions and test handler spares" and noted ...